Patients infected with human immunodeficiency virus (HIV) often suffer from herpesvirus infections as a result of immunosuppression. These infections can occur while patients are receiving antiretroviral therapy, and additional drugs required to treat their infection can adversely affect compliance. It would be useful to have antivirals with a broader spectrum of activity that included both HIV and the herpesviruses. We reported previously that alkoxyalkyl ester prodrugs of cidofovir are up to three orders of magnitude more active against herpesvirus replication and may be less toxic than the unmodified drug. To determine if this strategy would be effective for certain phosphonomethoxyethyl nucleoside phosphonates which are also active against HIV infections, the hexadecyloxypropyl (HDP) esters of 1-(phosphonomethoxyethyl)-cytosine (PME-C), 1-(phosphonomethoxyethyl)-5-bromo-cytosine (PME-5BrC), 1-(phosphonomethoxyethyl)-5-fluoro-cytosine (PME-5FC), 9-(phosphonomethoxyethyl)-2,4-diaminopurine (PME-DAP) and 9-(phosphonomethoxyethyl)-2-amino-4-cyclopropylaminopurine (PME-cPrDAP) were evaluated for activity against herpesvirus replication. The HDP esters were substantially more active than the unmodified acyclic nucleoside phosphonates indicating that esterification with alkoxyalkyl groups increases the antiviral activity of many acyclic nucleoside phosphonates. The most interesting compounds included HDP-PME-cPrDAP and HDP-PME-DAP, which were 12-to 43-fold more active than the parent nucleoside phosphonates against herpes simplex virus and cytomegalovirus, and HDP-PME-cPrDAP and HDP-PME-5BrC which were especially active against Epstein Barr virus. Results presented here indicate that HDP esterified acyclic nucleoside phosphonates with antiviral activity against HIV also inhibit the replication of some herpesviruses and can extend the spectrum of activity for these compounds.
INTRODUCTION
Nucleoside phosphonate antiviral agents have been approved for the treatment of human cytomegalovirus (HCMV), hepatitis B virus, and human immunodeficiency virus (HIV) infections and are under development as therapies for hepatitis C virus infections (11) . Many members of this versatile class of nucleotide analogs, such as 3-hydroxy-2-(phosphonomethoxy)propyl-cytosine (cidofovir, CDV), are highly effective against many different viruses and some are well tolerated in humans (12) .
However, certain nucleoside phosphonates, such as CDV, concentrate in the proximal tubules of the kidney resulting in dose-limiting nephrotoxicity (10) . Alkoxyalkyl ester prodrugs of CDV, such as hexadecyloxypropyl-CDV (HDP-CDV, CMX001), have been synthesized that are orally bioavailable and do not concentrate in the kidney and do not appear to cause nephrotoxicity (1, 8) . Alkoxyalkyl esterification of CDV also improved the efficacy of the compound by almost three orders of magnitude against HCMV in cell culture (30) , and was also effective when administered orally to mice infected with HCMV or murine cytomegalovirus (MCMV) (5, 18) . Similar improvements in efficacy were also observed with this drug against the other human herpesviruses, orthopoxviruses, adenoviruses and BK polyomavirus (3, 15, 19, 27, 30) .
This approach also proved to be successful when other phosphonomethoxyethyl purines and pyrimidines were converted to hexadecyloxypropyl (HDP), octadecyloxyethyl (ODE), and oleyloxyethyl esters and resulted in significant improvements in their efficacy against HIV, resulting in a thousand-fold improvement in the efficacy for HDP-PME-cPrDAP and HDP-PME-DAP (28) . Both these compounds were highly active and inhibited replication of HIV at concentrations of 10-16 pM.
We hypothesized that the esterification of these compounds may also improve their efficacy against other viruses and evaluated their activity against seven selected human herpesviruses. Results presented here confirmed that antiviral activity of both HDP-PME-cPrDAP and HDP-PME-DAP was improved significantly against many of the human herpesviruses. Increases in efficacy for these compounds were Plaque reduction assay for HSV-1, HSV-2, VZV, HCMV, and MCMV. Plaque reduction assays were performed with monolayers of HFF cells by methods described previously (30) . Briefly, 6-well plates containing confluent monolayers of HFF cells were infected to yield approximately 20-30 plaques per well. Compound dilutions were prepared in minimal essential medium (MEM) with 10% fetal bovine serum (FBS) and standard concentrations of L-glutamine, penicillin, and gentamicin. Growth media containing the compounds was added to duplicate wells and the plates were incubated at 37ºC with 5% CO 2 and 90% humidity. Cell monolayers were stained with a 1.5% solution of neutral red after an incubation of three days for HSV-1 and HSV-2, 8 days for HCMV, or 10 days for VZV. Assays for MCMV were performed by similar methods, but utilized primary mouse embryo fibroblast cells in 12-well plates and the cells were stained at 7 days after infection. All plaques were enumerated on a stereomicroscope at 10x magnification and compound concentrations that were sufficient to reduce viral replication by 50% (EC 50 ) values were calculated by standard methods (23).
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Determination of efficacy against EBV. Antiviral activity against EBV was determined in Daudi cells by methods described previously (30) Antiviral assays for HHV-6A and HHV-6B. Assessment of antiviral activity against HHV-6 was performed described previously (30) . Uninfected HSB-2 or MOLT-3 cells were infected by the addition of HHV-6A-infected HSB-2 cells or HHV-6B-infected MOLT-3 cells, respectively at a ratio of approximately 1 infected cell for every uninfected cell. Diluted compounds were added to the infected cells in 96-well plates, which were incubated for 7 days at 37°C. The accumulation of viral DNA was assessed by DNA hybridization and standard methods were used to interpolate EC 50 values.
Evaluation of cytotoxicity. Cytotoxicity was determined in parallel with antiviral activity in the same cell lines used to determine antiviral activity. In HFF cells, the compound concentration that reduced the uptake of the neutral red vital dye by 50% (CC 50 ) was used as a measure of toxicity.
Briefly, 2.5 x 10 4 low passage HFF cells were seeded into each well of 96 well tissue culture plates containing growth media and incubated for 24h at 37 º C in a CO 2 incubator. Media containing compound dilutions were then added to the plates, which were incubated for an additional 7 days. Cell monolayers were stained with a 0.01% solution of neutral red in PBS and incubated for 1h. Cells were washed and dye internalized by the cells was solubilized in 100µl of a 50% ethanol solution supplemented with 1% glacial acetic acid and the optical density was determined at 540nm. CellTiterGlo ® (Promega, Madison, WI) assays were also performed in a similar manner, but after 7 days of incubation 100µl of the media was removed from each well and 100µl of CellTiter-Glo ® reagent was added to each of the wells. Plates were mixed for 2 minutes and read on a luminometer to determine the number of live cells. In lymphocytes, cytotoxicity was determined with an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2H-tetrazolium) assay (Promega). Plates were prepared in the same manner as those for the antiviral assays described above, except that the cells were uninfected, or were not induced to undergo a lytic infection. Control wells were also included that contained only growth media. After incubation, 20 µl of MTS was added to each well, the plates were 

RESULTS.
Biological evaluation. A series of compounds ( Table 1) were evaluated to determine if the esterification of the parent phosphonomethoxyethyl purine and pyrimidine nucleoside phosphonates with HDP substituents would improve their efficacy against a series of human herpesviruses . Many of the prodrugs exhibited improved efficacy while not generally increasing their toxicity ( Table 2) , and resulted in improved selectivity indices (Tables 3-5 ). Most notable was the 10-to 40-fold improvement in the efficacy of HDP-PME-5BrC and HDP-PME-cPrDAP against the alphaherpesviruses (Table 3) .
Improved activity was not accompanied by increased cytotoxicity in HFF cells in the neutral red assay (Table 2) , and resulted in increases in the selective indices between 12-and 44-fold. Increased efficacy was also observed with HDP-PME-5BrC against HSV, yet did not appear to affect activity against VZV (Table 3) . Similar increases in the efficacy of these three compounds were also observed against HCMV ( Table 4 ). The most significant improvement against HCMV was with HDP-PME-cPrDAP that decreased the EC 50 by 20-fold and yielded a selective index of 5500. This compound also was also highly effective against MCMV with a selectivity index of >3667.
Efficacy of the esters was also increased against EBV and resulted in 800-and 142-fold improvements in EC 50 values for HDP-PME-5BrC and HDP-PME-cPrDAP, respectively (Table 5) .
Increased efficacy was also observed with HDP-PME-5BrC against this virus. While improvements in antiviral activity against HHV-6 strains were also observed with HDP-PME-cPrDAP yielding 20-to 128-fold improvements over the PME-cPrDAP, the increased efficacy was also accompanied by increased cytotoxicity in these cell culture systems and did not result in improved selective indices (Table 5) . The in vitro antiviral activity of purine and pyrimidine nucleoside phosphonomethoxyethylphosphonates against seven selected human herpesviruses was significantly improved through their esterification with the HDP alkoxyalkyl moiety. The synthesis of the molecules tested here was reported previously and their antiviral activity against HIV was also shown to be dramatically improved by the addition of the HDP esters (28) . The most impressive effects were observed with HDP-PME-DAP and HDP-PME-cPrDAP, which increased their efficacy against HIV by 4 orders of magnitude over the unesterified nucleoside phosphonates. The most potent analog against HIV was HDP-PME-cPrDAP which was active at concentrations below 10 pM, and was also the most active compound against EBV cells. Subsequent studies in animal models will be required to assess these and other potential toxicities of these compounds.
DISCUSSION
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The human herpesviruses also appeared to differ in their susceptibility to some of the specific phosphonomethoxyethyl nucleoside phosphonates in these studies. For example, VZV, HCMV, and EBV were more sensitive to PME-cPrDAP than HSV-1 or HSV-2, and occurred irrespective of esterification with HDP. Thus, the increased efficacy against these viruses appears to be a characteristic herpesviruses. These data, together with those presented here will be used to select candidate compounds for further testing in animal models. While HDP-PME-cPrDAP appears to be an excellent candidate, it is possible that other related analogs might exhibit even better activity. The planned in vivo studies will be critical because they will identify the most potent analogs that are well tolerated in animals.
Esterification of CDV and cyclic CDV with HDP has also been shown to improve the efficacy of these molecules by three orders of magnitude against the herpesviruses (3, 29, 30) . Improved activity was not limited to in vitro systems, but was also was observed against HCMV and MCMV in experimental animal infections (5, 18) . Enhanced in vitro efficacy was observed also against the orthopoxviruses (4, 17, 19) and this increased activity also translated to superior efficacy in animal models for HDP-CDV, as well as hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-
phosphonylmethoxypropyl)-adenine] [(S)-HPMPA] and octadecyloxyethyl-(S)-HPMPA, which were
shown to reduce mortality in lethal models of orthopoxvirus infection (7, 24-26). However, one of the most important attributes of HDP and ODE esters is their oral bioavailability, and provides an important advantage over the free nucleoside phosphonates that must be administered parenterally (8) and exhibit nephrotoxicity.
Data presented here provide additional evidence that the esterification of pyrimidine and purine nucleoside posphonates that are active against HIV with an alkoxyalkyl moiety (HDP) (28) , also substantially improves their antiviral activity against the herpesviruses. This finding is significant because the extended spectrum of activity exhibited by these molecules might also be able to suppress
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on October 15, 2017 by guest http://aac.asm.org/ Downloaded from opportunistic herpesvirus infections. This is relevant to the treatment of herpesvirus infections in this clinical setting at two critical levels. First, additional therapies are required to treat these infections and the therapies of choice for opportunistic infections, such as HCMV possess significant dose limiting toxicities (2, 6). Second, the development of resistance to existing herpesvirus drugs is a significant problem in the immunosuppressed (13, 20) . Thus, therapies for HIV infections that also suppress the replication of opportunistic herpesviruses should reduce virus loads during reactivation events, and would be predicted to reduce the development of drug resistant variants. HSV infections have also been shown to upregulate HIV replication (14) , and a recent clinical study has shown that the suppression of HSV replication with valacyclovir can reduce the levels of HIV-1 RNA levels (22) . Although the mechanism is likely indirect, it is possible that the inhibition of herpesvirus replication by a drug may actually increase its efficacy against HIV. The additional protection afforded by broad spectrum agents such as those described here would be of significant value in immunosuppressed individuals and further development of such agents is warranted. Table 1 . Names and abbreviations of alkoxyalkyl esters of nucleoside phosphonates. Abbreviation Name PME-C 1-(phosphonomethoxyethyl)-cytosine HDP-PME-C Hexadecyloxypropyl 1-(phosphonomethoxyethyl)-cytosine PME-5BrC 1-(phosphonomethoxyethyl)-5-bromo-cytosine HDP-PME-5BrC
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Hexadecyloxypropyl 1-(phosphonomethoxyethyl)-5-bromo-cytosine PME-5FC 1-(phosphonomethoxyethyl)-5-fluoro-cytosine HDP-PME-5FC Hexadecyloxypropyl 1-(phosphonomethoxyethyl)-5-fluoro-cytosine PME-DAP 9-(phosphonomethoxyethyl)-2,4-diaminopurine HSP-PME-DAP Hexadecyloxypropyl 9-(phosphonomethoxyethyl)-2,4-diaminopurine PME-cPrDAP 9-(phosphonomethoxyethyl)-2-amino-4-cyclopropylaminopurine HDP-PME-cPrDAP Hexadecyloxypropyl 9-(phosphonomethoxyethyl)-2-amino-4-cyclopropylaminopurine 
MOLT-3 Cells (MTS)
PME-C >300 220 ± 54 >100 >50 ± 0 >50
HDP-PME-C >300 200 ± 74 >100 >50 >50 ± 0 PME-5BrC >300 200 ± 6 27 3.9 ± 2.8 84 ± 13
HDP-PME-5BrC >300 35 ± 5 >100 >41 ± 12 >50 ± 0 PME-5FC NT 220 ± 58 NT >41 ± 13 >50 ± 0 HDP-PME-5FC 35 ± 3 33 ± 2 >100 22.6 >50 PME-DAP >100 170 ± 36 >50 >56 ± 9 39 ± 6 HDP-PME-DAP 120 ± 42 170 ± 59 >50 6. 50 SI PME-C >20 ± 0 <150 63 ± 7 >480
A C C E P T E D
HDP-PME-C >20 ± 0 <150 >20 ± 0 <150 PME-5BrC >20 ± 0 <150 >20 ± 0 <150
HDP-PME-5BrC 4.8 ± 3 >63 1.3 ± 1 >230 PME-5FC >20 ± 0 <11 78 ± 1 2.8 HDP-PME-5FC 2 ± 2 18 0.08 ± 0.01 440 PME-DAP 13 ± 7 >8 0.2 ± 0.1 >500
HDP-PME-DAP 0.5 ± 0.1 240 0.5 ± 0.1 240 PME-cPrDAP 0.4 ± 0.01 250 <0.06 ± 0.05 >1700
HDP-PME-cPrDAP 0.02 ± 0.01 5500 <0.03 ± 0 >3700 a. Effective concentration that reduced plaque formation by 50% (EC 50 ). All values shown are the average of at least two experiments and are given in units of µM. b. Selectivity index (SI) is the ratio of the EC 50 divided by the concentration of the compound that reduced cell viability by 50% (CC 50 ) as determined in HFF cells by the neutral red uptake assay. PME-C >41 ± 1.3 <2.4 >50 ± 0 1 >50 ± 0 1 HDP-PME-C >50 ± 0 <2 >50 ± 0 1 >50 ± 0 1 PME-5BrC 24 ± 1.5 1.1 >50 ± 0 1 >47 ± 4 <2 HDP-PME-5BrC 0.03 ± 0.03 >3400 38 ± 13 1 >45 ± 6 1 PME-5FC >50 ± 0 >50 ± 0 1 >50 ± 0 1 HDP-PME-5FC
1.3 ± 0.2 >77 7.2 ± 0.6 >6 37 ± 4.5 >1 PME-DAP 1.2 ± 0.9 >42 15 ± 6 >4 28 ± 10 1 HDP-PME-DAP 0.8 ± 0.8 >63 2.0 ± 0.1 3 34 ± 2.3 1 PME-cPrDAP 0.1 ± 0.1 200 1.0 ± 0.9 3 6.4 ± 1.6 1 HDP-PME-cPrDAP 0.0007 ± 0 >71000 0.05 ± 0.01 1 0.05 ± 0.007 6 a. Effective concentration that reduced plaque formation by 50% (EC 50 ). All values shown are the average of at least two experiments and are given in units of µM. b. Selectivity index (SI) is the ratio of the EC 50 divided by the concentration of the compound that reduced cell viability by 50% (CC 50 ). CC 50 values used to calculate SI values were obtained with MTS assays in Daudi, HSB-2, and MOLT-3 cells for EBV, HHV-6A, and HHV-6B, respectively.
